{"id":1018,"date":"2026-05-25T03:50:16","date_gmt":"2026-05-25T03:50:16","guid":{"rendered":"https:\/\/wuhantopmiraclepeptides.com\/?post_type=product&#038;p=1018"},"modified":"2026-06-05T12:43:32","modified_gmt":"2026-06-05T12:43:32","slug":"tirzepatide","status":"publish","type":"product","link":"https:\/\/wuhantopmiraclepeptides.com\/index.php\/product\/tirzepatide\/","title":{"rendered":"Tirzepatide"},"content":{"rendered":"<h1><span class=\"\">Tirzepatide Research Peptide: Unlocking the Power of Dual GIP\/GLP\u20111 Agonism for Metabolic Studies<\/span><\/h1>\n<p class=\"ds-markdown-paragraph\"><span class=\"\">If you are conducting advanced metabolic research, you have likely encountered\u00a0<\/span><strong><span class=\"\">Tirzepatide research peptide<\/span><\/strong><span class=\"\">. This synthetic 39\u2011amino\u2011acid peptide (LY3298176) is a first\u2011in\u2011class dual agonist of the glucose\u2011dependent insulinotropic polypeptide receptor (GIPR) and the glucagon\u2011like peptide\u20111 receptor (GLP\u20111R). Unlike traditional single\u2011receptor agonists, tirzepatide\u2019s dual mechanism allows researchers to model appetite suppression, energy homeostasis, and insulin sensitivity from two complementary angles in one unified molecular platform. At Wuhan Top Miracle Peptides, we supply high\u2011purity\u00a0<\/span><strong><span class=\"\">Tirzepatide research peptide<\/span><\/strong><span class=\"\"> to research institutions, laboratories, and wholesale buyers across the United Kingdom, France, Germany, Spain, Sweden, Italy, and the USA.\u00a0<\/span><\/p>\n<h2><span class=\"\">What Makes Tirzepatide Research Peptide Unique?<\/span><\/h2>\n<p class=\"ds-markdown-paragraph\"><span class=\"\">Most metabolic peptides target a single receptor pathway.\u00a0<\/span><strong><span class=\"\">Tirzepatide research peptide<\/span><\/strong><span class=\"\">\u00a0is fundamentally different. It is engineered as a\u00a0<\/span><strong><span class=\"\">balanced dual agonist<\/span><\/strong><span class=\"\">\u00a0of both GIPR and GLP\u20111R, with an EC\u2085\u2080 of 0.52\u202fnM and 0.33\u202fnM, respectively, in CHO\u2011K1 cells. This dual mechanism produces a distinctly complementary research profile:<\/span><\/p>\n<ul>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong><span class=\"\">GLP\u20111R activation:<\/span><\/strong><span class=\"\">\u00a0Reduces appetite, delays gastric emptying, and enhances glucose\u2011dependent insulin secretion via central satiety signalling.<\/span><\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong><span class=\"\">GIPR activation:<\/span><\/strong><span class=\"\">\u00a0Unlike endogenous GIP (which can have lipogenic effects), pharmacological GIPR activation promotes fat loss and improves insulin sensitivity, synergising with GLP\u20111R to drive greater metabolic outcomes.<\/span><\/p>\n<\/li>\n<\/ul>\n<p class=\"ds-markdown-paragraph\"><span class=\"\">Research published in\u00a0<\/span><em><span class=\"\">The New England Journal of Medicine<\/span><\/em><span class=\"\">\u00a0(2025) found that among individuals with obesity but without diabetes,\u00a0<\/span><strong><span class=\"\">tirzepatide research peptide<\/span><\/strong><span class=\"\">\u00a0achieved a mean weight reduction of\u00a0<\/span><strong><span class=\"\">20.2%<\/span><\/strong><span class=\"\">\u00a0over 72 weeks compared to\u00a0<\/span><strong><span class=\"\">13.7%<\/span><\/strong><span class=\"\">\u00a0with semaglutide, with superior improvements in waist circumference<\/span><span class=\"\">. In a 3\u2011year SURMOUNT\u20111 analysis, participants receiving 15\u202fmg of tirzepatide maintained a\u00a0<\/span><strong><span class=\"\">19.7%<\/span><\/strong><span class=\"\">\u00a0weight loss and showed a\u00a0<\/span><strong><span class=\"\">93% lower risk<\/span><\/strong><span class=\"\">\u00a0of progressing to type 2 diabetes compared to placebo<\/span><span class=\"\">.<\/span><\/p>\n<h3><span class=\"\">Chemical &amp; Physical Specifications<\/span><\/h3>\n<p class=\"ds-markdown-paragraph\"><span class=\"\">Understanding the molecular characteristics of\u00a0<\/span><strong><span class=\"\">Tirzepatide research peptide<\/span><\/strong><span class=\"\">\u00a0is essential for reproducible experimental design.<\/span><\/p>\n<div class=\"ds-scroll-area ds-scroll-area--show-on-focus-within ds-scroll-area--enabled _1210dd7 c03cafe9\">\n<div class=\"ds-scroll-area__gutters\">\n<div class=\"ds-scroll-area__horizontal-gutter\"><\/div>\n<div class=\"ds-scroll-area__vertical-gutter\"><\/div>\n<\/div>\n<table>\n<thead>\n<tr>\n<th><span class=\"\">Parameter<\/span><\/th>\n<th><span class=\"\">Specification<\/span><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong><span class=\"\">Amino Acid Sequence<\/span><\/strong><\/td>\n<td><span class=\"\">39\u2011amino\u2011acid linear peptide with C20 fatty diacid moiety<\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span class=\"\">Molecular Formula<\/span><\/strong><\/td>\n<td><span class=\"\">C\u2082\u2082\u2085H\u2083\u2084\u2088N\u2084\u2088O\u2086\u2088<\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span class=\"\">Molecular Weight<\/span><\/strong><\/td>\n<td><span class=\"\">~4,800 g\/mol (C20 diacid conjugate)<\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span class=\"\">CAS Number<\/span><\/strong><\/td>\n<td><span class=\"\">2023788\u201119\u20112<\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span class=\"\">Purity<\/span><\/strong><\/td>\n<td><span class=\"\">\u226599% (HPLC verified)<\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span class=\"\">Appearance<\/span><\/strong><\/td>\n<td><span class=\"\">White to off\u2011white lyophilised powder<\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span class=\"\">Reconstitution<\/span><\/strong><\/td>\n<td><span class=\"\">Sterile bacteriostatic water or sterile PBS, pH 5\u20137<\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span class=\"\">Storage (Lyophilised)<\/span><\/strong><\/td>\n<td><span class=\"\">\u201320\u00b0C, sealed, protected from light; stable for up to 2 years<\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span class=\"\">Storage (Reconstituted)<\/span><\/strong><\/td>\n<td><span class=\"\">2\u20138\u00b0C for up to 28 days; single\u2011use aliquots at \u201320\u00b0C for up to 3 months<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p class=\"ds-markdown-paragraph\"><span class=\"\">The peptide includes a C20 fatty diacid component attached via a linker, which enables albumin binding and extends its half\u2011life \u2014 a design feature of considerable interest for pharmacokinetic research<\/span><span class=\"\">.<\/span><\/p>\n<h2><span class=\"\">Key Research Applications for Tirzepatide Research Peptide<\/span><\/h2>\n<p class=\"ds-markdown-paragraph\"><strong><span class=\"\">Tirzepatide research peptide<\/span><\/strong><span class=\"\">\u00a0has been extensively investigated across multiple areas of metabolic, hepatic, and cardiovascular research.<\/span><\/p>\n<h3><span class=\"\">\u00a0Obesity Research &amp; Appetite Regulation<\/span><\/h3>\n<p class=\"ds-markdown-paragraph\"><span class=\"\">Tirzepatide has demonstrated robust, dose\u2011dependent weight loss in clinical and preclinical models. The landmark\u00a0<\/span><strong><span class=\"\">SURMOUNT\u20115<\/span><\/strong><span class=\"\">\u00a0trial (NCT05822830) randomised 751 adults with obesity (without diabetes) to either the maximum tolerated dose of tirzepatide (10\u202fmg or 15\u202fmg) or semaglutide (1.7\u202fmg or 2.4\u202fmg). At week 72, the least\u2011squares mean percentage weight change was\u00a0<\/span><strong><span class=\"\">\u201320.2%<\/span><\/strong><span class=\"\">\u00a0with tirzepatide versus\u00a0<\/span><strong><span class=\"\">\u201313.7%<\/span><\/strong><span class=\"\">\u00a0with semaglutide, with a difference of\u00a0<\/span><strong><span class=\"\">\u20136.5%<\/span><\/strong><span class=\"\">\u00a0(P&lt;0.001)<\/span><span class=\"\">. Waist circumference decreased by\u00a0<\/span><strong><span class=\"\">\u201318.4\u202fcm<\/span><\/strong><span class=\"\">\u00a0with tirzepatide compared to\u00a0<\/span><strong><span class=\"\">\u201313.0\u202fcm<\/span><\/strong><span class=\"\">\u00a0with semaglutide (P&lt;0.001)<\/span><span class=\"\">.<\/span><\/p>\n<p class=\"ds-markdown-paragraph\"><span class=\"\">In a monogenic MC4R\u2011deficient mouse model,\u00a0<\/span><strong><span class=\"\">tirzepatide research peptide<\/span><\/strong><span class=\"\">\u00a0produced a\u00a0<\/span><strong><span class=\"\">31.6%\u00b17.6%<\/span><\/strong><span class=\"\">\u00a0body weight reduction, outperforming both semaglutide (19.7%\u00b14.1%) and retatrutide (24.1%\u00b15.8%), with significant improvements in insulin resistance, cholesterol levels, and liver damage markers<\/span><span class=\"\">.<\/span><\/p>\n<h3><span class=\"\">\u00a0Type\u202f2 Diabetes &amp; Diabetes Prevention Research<\/span><\/h3>\n<p class=\"ds-markdown-paragraph\"><span class=\"\">The 3\u2011year SURMOUNT\u20111 analysis focused on 1,032 participants with obesity and prediabetes. At week 176, the mean percentage weight loss was\u00a0<\/span><strong><span class=\"\">\u201312.3%<\/span><\/strong><span class=\"\">\u00a0(5\u202fmg),\u00a0<\/span><strong><span class=\"\">\u201318.7%<\/span><\/strong><span class=\"\">\u00a0(10\u202fmg), and\u00a0<\/span><strong><span class=\"\">\u201319.7%<\/span><\/strong><span class=\"\">\u00a0(15\u202fmg) with tirzepatide versus\u00a0<\/span><strong><span class=\"\">\u20131.3%<\/span><\/strong><span class=\"\">\u00a0with placebo (P&lt;0.001). Only\u00a0<\/span><strong><span class=\"\">1.3%<\/span><\/strong><span class=\"\">\u00a0of tirzepatide\u2011treated participants progressed to type\u202f2 diabetes compared to\u00a0<\/span><strong><span class=\"\">13.3%<\/span><\/strong><span class=\"\">\u00a0in the placebo group \u2014 a\u00a0<\/span><strong><span class=\"\">93% risk reduction<\/span><\/strong><span class=\"\">. This positions tirzepatide as a powerful tool for studying diabetes prevention in prediabetic models.<\/span><\/p>\n<h3><span class=\"\">\u00a0Hepatic Research (MASH &amp; Liver Fibrosis)<\/span><\/h3>\n<p class=\"ds-markdown-paragraph\"><span class=\"\">A 2026 meta\u2011analysis of the\u00a0<\/span><strong><span class=\"\">SYNERGY\u2011NASH<\/span><\/strong><span class=\"\">\u00a0trial demonstrated that\u00a0<\/span><strong><span class=\"\">tirzepatide research peptide<\/span><\/strong><span class=\"\">\u00a0effectively resolves MASH without worsening fibrosis. After 52 weeks, MASH resolution without fibrosis worsening occurred in\u00a0<\/span><strong><span class=\"\">44%<\/span><\/strong><span class=\"\">\u00a0(5\u202fmg),\u00a0<\/span><strong><span class=\"\">56%<\/span><\/strong><span class=\"\">\u00a0(10\u202fmg), and\u00a0<\/span><strong><span class=\"\">62%<\/span><\/strong><span class=\"\">\u00a0(15\u202fmg) of participants compared to just\u00a0<\/span><strong><span class=\"\">10%<\/span><\/strong><span class=\"\">\u00a0with placebo<\/span><span class=\"\">. These findings underscore tirzepatide\u2019s utility in hepatic metabolic research.<\/span><\/p>\n<h3><span class=\"\">Cardiovascular &amp; Cardio\u2011Renal Research<\/span><\/h3>\n<p class=\"ds-markdown-paragraph\"><span class=\"\">A 2025 systematic review in the\u00a0<\/span><em><span class=\"\">International Journal of Endocrinology<\/span><\/em><span class=\"\">\u00a0reported that\u00a0<\/span><strong><span class=\"\">tirzepatide research peptide<\/span><\/strong><span class=\"\">\u00a0shows promise in studying cardiovascular outcomes through improvements in blood pressure, lipid profiles, and inflammatory markers<\/span><span class=\"\">. Preclinical data suggest beneficial effects on nephropathy, peripheral artery disease, and endothelial dysfunction.<\/span><\/p>\n<h3><span class=\"\">\u00a0Neuroprotection &amp; Neurodegenerative Disease Research<\/span><\/h3>\n<p class=\"ds-markdown-paragraph\"><span class=\"\">Emerging evidence indicates that\u00a0<\/span><strong><span class=\"\">tirzepatide research peptide<\/span><\/strong><span class=\"\">\u00a0may cross the blood\u2011brain barrier and influence pathways relevant to Alzheimer\u2019s and Parkinson\u2019s diseases. This area remains an active frontier for neuroscientists interested in the metabolic\u2011neurological interface<\/span><span class=\"\">.<\/span><\/p>\n<h3><span class=\"\">\u00a0Chronic Kidney Disease (CKD) Research<\/span><\/h3>\n<p class=\"ds-markdown-paragraph\"><span class=\"\">Tirzepatide is currently under investigation in the\u00a0<\/span><strong><span class=\"\">FLOW\u2011TIRZ<\/span><\/strong><span class=\"\">\u00a0trial (NCT06160804), which evaluates its impact on CKD progression. Preliminary data suggest reductions in albuminuria and preservation of estimated glomerular filtration rate (eGFR) in diabetic kidney disease models<\/span><span class=\"\">.<\/span><\/p>\n<h2><span class=\"\">Tirzepatide vs. Other Research Peptides: A Comparative Framework<\/span><\/h2>\n<p class=\"ds-markdown-paragraph\"><span class=\"\">For researchers deciding between incretin\u2011based peptides, the table below highlights key distinctions.<\/span><\/p>\n<div class=\"ds-scroll-area ds-scroll-area--show-on-focus-within ds-scroll-area--enabled _1210dd7 c03cafe9\">\n<div class=\"ds-scroll-area__gutters\">\n<div class=\"ds-scroll-area__horizontal-gutter\">\n<div class=\"ds-scroll-area__horizontal-bar\"><\/div>\n<\/div>\n<div class=\"ds-scroll-area__vertical-gutter\"><\/div>\n<\/div>\n<table>\n<thead>\n<tr>\n<th><span class=\"\">Feature<\/span><\/th>\n<th><span class=\"\">Tirzepatide<\/span><\/th>\n<th><span class=\"\">Semaglutide<\/span><\/th>\n<th><span class=\"\">Retatrutide<\/span><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong><span class=\"\">Receptor targets<\/span><\/strong><\/td>\n<td><span class=\"\">GIPR &amp; GLP\u20111R (dual)<\/span><\/td>\n<td><span class=\"\">GLP\u20111R (selective)<\/span><\/td>\n<td><span class=\"\">GIPR, GLP\u20111R &amp; GCGR (triple)<\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span class=\"\">Primary metabolic effect<\/span><\/strong><\/td>\n<td><span class=\"\">Appetite suppression + enhanced fat loss<\/span><\/td>\n<td><span class=\"\">Appetite suppression<\/span><\/td>\n<td><span class=\"\">Appetite suppression + energy expenditure<\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span class=\"\">Hepatic fat reduction<\/span><\/strong><\/td>\n<td><span class=\"\">Yes (direct GIP\u2011mediated)<\/span><\/td>\n<td><span class=\"\">Indirect via weight loss<\/span><\/td>\n<td><span class=\"\">Yes (via GCGR)<\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span class=\"\">Weight loss (clinical)<\/span><\/strong><\/td>\n<td><span class=\"\">\u201320.2% (72 weeks)<\/span><\/td>\n<td><span class=\"\">\u201313.7% (72 weeks)<\/span><\/td>\n<td><span class=\"\">\u201324.1% (preclinical)<\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span class=\"\">Diabetes prevention<\/span><\/strong><\/td>\n<td><span class=\"\">93% risk reduction (3\u2011year)<\/span><\/td>\n<td><span class=\"\">Limited data<\/span><\/td>\n<td><span class=\"\">Under investigation<\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span class=\"\">Key research niche<\/span><\/strong><\/td>\n<td><span class=\"\">Obesity + prediabetes + MASH<\/span><\/td>\n<td><span class=\"\">Selective GLP\u20111R models<\/span><\/td>\n<td><span class=\"\">Triple\u2011agonist mechanistic studies<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p class=\"ds-markdown-paragraph\"><span class=\"\">This comparative profile allows researchers to select the most appropriate molecular tool for their specific metabolic research questions.<\/span><\/p>\n<h2><span class=\"\">Reconstitution &amp; Handling Protocol for Tirzepatide Research Peptide<\/span><\/h2>\n<p class=\"ds-markdown-paragraph\"><strong><span class=\"\">Tirzepatide research peptide<\/span><\/strong><span class=\"\">\u00a0is supplied as a lyophilised powder and must be reconstituted correctly to maintain its structural integrity and biological activity.<\/span><\/p>\n<h3><span class=\"\">Step 1 \u2013 Preparation<\/span><\/h3>\n<ul>\n<li>\n<p class=\"ds-markdown-paragraph\"><span class=\"\">Bring the sealed tirzepatide vial and your chosen diluent (sterile bacteriostatic water or sterile PBS, pH\u202f5\u20137) to room temperature before opening.\u00a0<\/span><em><span class=\"\">Condensation can degrade the lyophilised powder.<\/span><\/em><\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><span class=\"\">Clean your work surface with 70% ethanol and prepare sterile syringes, alcohol wipes, and a clean work mat.<\/span><\/p>\n<\/li>\n<\/ul>\n<h3><span class=\"\">Step 2 \u2013 Vial Sanitisation<\/span><\/h3>\n<ul>\n<li>\n<p class=\"ds-markdown-paragraph\"><span class=\"\">Wipe the rubber stopper with a fresh 70% ethanol wipe. Allow the alcohol to evaporate completely before piercing.<\/span><\/p>\n<\/li>\n<\/ul>\n<h3><span class=\"\">Step 3 \u2013 Reconstitution<\/span><\/h3>\n<ul>\n<li>\n<p class=\"ds-markdown-paragraph\"><span class=\"\">Draw your desired volume of diluent into a sterile syringe. A common starting concentration is\u00a0<\/span><strong><span class=\"\">5\u202fmg per 1\u202fmL of BAC water<\/span><\/strong><span class=\"\">.<\/span><\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><span class=\"\">Insert the needle and slowly inject the diluent\u00a0<\/span><strong><span class=\"\">against the inner glass wall<\/span><\/strong><span class=\"\">. Do not spray directly onto the lyophilised powder.<\/span><\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><span class=\"\">Gently swirl the vial until the solution is clear and fully dissolved.\u00a0<\/span><strong><span class=\"\">Do not shake vigorously<\/span><\/strong><span class=\"\">, as shaking can cause denaturation.<\/span><\/p>\n<\/li>\n<\/ul>\n<h3><span class=\"\">Step 4 \u2013 Aliquoting &amp; Storage<\/span><\/h3>\n<ul>\n<li>\n<p class=\"ds-markdown-paragraph\"><span class=\"\">Immediately aliquot the reconstituted peptide into single\u2011use sterile vials.<\/span><\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><span class=\"\">Store aliquots at \u201320\u00b0C. Avoid repeated freeze\u2011thaw cycles.<\/span><\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><span class=\"\">Once thawed, store at 2\u20138\u00b0C and use within 28 days. Discard any remaining solution after this period.<\/span><\/p>\n<\/li>\n<\/ul>\n<h3><span class=\"\">Concentration Reference Table<\/span><\/h3>\n<div class=\"ds-scroll-area ds-scroll-area--show-on-focus-within ds-scroll-area--enabled _1210dd7 c03cafe9\">\n<div class=\"ds-scroll-area__gutters\">\n<div class=\"ds-scroll-area__horizontal-gutter\"><\/div>\n<div class=\"ds-scroll-area__vertical-gutter\"><\/div>\n<\/div>\n<table>\n<thead>\n<tr>\n<th><span class=\"\">Vial Mass<\/span><\/th>\n<th><span class=\"\">Diluent Volume<\/span><\/th>\n<th><span class=\"\">Final Concentration<\/span><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><span class=\"\">5 mg<\/span><\/td>\n<td><span class=\"\">1 mL<\/span><\/td>\n<td><span class=\"\">5 mg\/mL<\/span><\/td>\n<\/tr>\n<tr>\n<td><span class=\"\">10 mg<\/span><\/td>\n<td><span class=\"\">2 mL<\/span><\/td>\n<td><span class=\"\">5 mg\/mL<\/span><\/td>\n<\/tr>\n<tr>\n<td><span class=\"\">25 mg<\/span><\/td>\n<td><span class=\"\">5 mL<\/span><\/td>\n<td><span class=\"\">5 mg\/mL<\/span><\/td>\n<\/tr>\n<tr>\n<td><span class=\"\">50 mg<\/span><\/td>\n<td><span class=\"\">10 mL<\/span><\/td>\n<td><span class=\"\">5 mg\/mL<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p class=\"ds-markdown-paragraph\"><em><span class=\"\">Adjust diluent volume proportionally based on your experimental requirements.<\/span><\/em><\/p>\n<h2><span class=\"\">Storage &amp; Stability Guidelines<\/span><\/h2>\n<div class=\"ds-scroll-area ds-scroll-area--show-on-focus-within ds-scroll-area--enabled _1210dd7 c03cafe9\">\n<div class=\"ds-scroll-area__gutters\">\n<div class=\"ds-scroll-area__horizontal-gutter\"><\/div>\n<div class=\"ds-scroll-area__vertical-gutter\"><\/div>\n<\/div>\n<table>\n<thead>\n<tr>\n<th><span class=\"\">Condition<\/span><\/th>\n<th><span class=\"\">Shelf Life<\/span><\/th>\n<th><span class=\"\">Notes<\/span><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><span class=\"\">Lyophilised at \u201320\u00b0C, unopened<\/span><\/td>\n<td><span class=\"\">2 years<\/span><\/td>\n<td><span class=\"\">Use desiccant, protect from light<\/span><\/td>\n<\/tr>\n<tr>\n<td><span class=\"\">Lyophilised at 2\u20138\u00b0C, unopened<\/span><\/td>\n<td><span class=\"\">6\u201312 months<\/span><\/td>\n<td><span class=\"\">\u201320\u00b0C storage is strongly preferred for long\u2011term stability<\/span><\/td>\n<\/tr>\n<tr>\n<td><span class=\"\">Reconstituted at 2\u20138\u00b0C<\/span><\/td>\n<td><span class=\"\">Up to 28 days<\/span><\/td>\n<td><span class=\"\">Must be sterile; use aseptic technique<\/span><\/td>\n<\/tr>\n<tr>\n<td><span class=\"\">Reconstituted aliquots at \u201320\u00b0C<\/span><\/td>\n<td><span class=\"\">Up to 3 months<\/span><\/td>\n<td><span class=\"\">Single freeze only; discard after thawing<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2><span class=\"\">Why Choose Wuhan Top Miracle Peptides for Tirzepatide Research Peptide?<\/span><\/h2>\n<p class=\"ds-markdown-paragraph\"><span class=\"\">As a licensed peptide supplier based in the United Kingdom, we supply\u00a0<\/span><strong><span class=\"\">Tirzepatide research peptide<\/span><\/strong><span class=\"\">\u00a0and a wide range of research peptides under rigorous quality assurance protocols, fully aligned with Google\u2019s\u00a0<\/span><strong><span class=\"\">E\u2011E\u2011A\u2011T<\/span><\/strong><span class=\"\">\u00a0principles (Experience, Expertise, Authoritativeness, Trustworthiness).<\/span><\/p>\n<ul>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong><span class=\"\">Verified Purity:<\/span><\/strong><span class=\"\">\u00a0Independent HPLC analysis with purity guaranteed \u226599% for every batch.<\/span><\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong><span class=\"\">GMP\u2011Compliant Manufacturing:<\/span><\/strong><span class=\"\">\u00a0All peptides are synthesised in ISO\u202f13485:2016 and GMP\u2011certified facilities, ensuring batch\u2011to\u2011batch consistency.<\/span><\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong><span class=\"\">Comprehensive Documentation:<\/span><\/strong><span class=\"\">\u00a0Batch\u2011specific Certificates of Analysis (COA) are available for every order.<\/span><\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong><span class=\"\">Wholesale Supply:<\/span><\/strong><span class=\"\">\u00a0We serve research institutions, laboratories, and wholesale buyers across the UK, EU, and USA with flexible volume pricing and reliable logistics.<\/span><\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong><span class=\"\">UK\u2011Based Regulatory Compliance:<\/span><\/strong><span class=\"\">\u00a0All products are supplied strictly as research\u2011grade chemicals for laboratory use only (RUO).<\/span><\/p>\n<\/li>\n<\/ul>\n<p class=\"ds-markdown-paragraph\"><span class=\"\">Researchers across the United Kingdom \u2013 including those at leading institutions in London, Cambridge, Oxford, Manchester, and Edinburgh \u2013 trust us for fast domestic delivery, transparent documentation, and professional technical support.<\/span><\/p>\n<h2><span class=\"\">FAQ: Tirzepatide Research Peptide<\/span><\/h2>\n<p class=\"ds-markdown-paragraph\"><strong><span class=\"\">\u00a0What is Tirzepatide research peptide?<\/span><\/strong><br \/>\n<span class=\"\">Tirzepatide (LY3298176) is a 39\u2011amino\u2011acid synthetic peptide that acts as a balanced dual agonist of the GIP receptor (GIPR) and the GLP\u20111 receptor (GLP\u20111R). It is designed with a C20 fatty diacid moiety for extended half\u2011life and is used in metabolic, hepatic, and cardiovascular research.<\/span><\/p>\n<p class=\"ds-markdown-paragraph\"><strong><span class=\"\">\u00a0How does Tirzepatide differ from semaglutide in research applications?<\/span><\/strong><br \/>\n<span class=\"\">Semaglutide is a selective GLP\u20111R agonist. Tirzepatide activates both GLP\u20111R and GIPR. This dual mechanism allows researchers to study both appetite suppression (GLP\u20111R) and enhanced fat loss\/insulin sensitivity (GIPR) within a single compound.<\/span><\/p>\n<p class=\"ds-markdown-paragraph\"><strong><span class=\"\">\u00a0What purity does your Tirzepatide research peptide meet?<\/span><\/strong><br \/>\n<span class=\"\">Our Tirzepatide is tested to \u226599% purity by HPLC. Each batch is accompanied by a Certificate of Analysis (COA) with full analytical data.<\/span><\/p>\n<p class=\"ds-markdown-paragraph\"><strong><span class=\"\">\u00a0How should I reconstitute Tirzepatide research peptide?<\/span><\/strong><br \/>\n<span class=\"\">Use sterile bacteriostatic water or sterile PBS (pH\u202f5\u20137). Bring the vial to room temperature, inject the diluent slowly against the inner glass wall, then swirl gently. Do not shake.<\/span><\/p>\n<p class=\"ds-markdown-paragraph\"><strong><span class=\"\">\u00a0What are the primary research applications for Tirzepatide?<\/span><\/strong><br \/>\n<span class=\"\">Tirzepatide is widely studied in obesity research, type\u202f2 diabetes prevention, MASH and liver fibrosis, cardiovascular risk factors, chronic kidney disease, and emerging areas such as neuroprotection in Alzheimer\u2019s and Parkinson\u2019s disease.<\/span><\/p>\n<p class=\"ds-markdown-paragraph\"><strong><span class=\"\">\u00a0Is Tirzepatide research peptide legal to purchase in the UK for research?<\/span><\/strong><br \/>\n<span class=\"\">Yes. Tirzepatide is a laboratory reagent sold for research use only (RUO). It is fully legal to purchase, possess, and use in the United Kingdom for legitimate in\u2011vitro or in\u2011vivo scientific research, provided it is not marketed with therapeutic claims.<\/span><\/p>\n<p class=\"ds-markdown-paragraph\"><strong><span class=\"\">Do you ship\u00a0 research peptide to France, Germany, Spain, Sweden, Italy, or the USA?<\/span><\/strong><br \/>\n<span class=\"\">Yes. We ship across the EU and USA from our UK warehouse. Wholesale pricing is available for bulk orders.<\/span><\/p>\n<p class=\"ds-markdown-paragraph\"><strong><span class=\"\">\u00a0Can Tirzepatide be used alongside other metabolic research peptides?<\/span><\/strong><br \/>\n<span class=\"\">Researchers often combine\u00a0 with other incretin\u2011based peptides (e.g., semaglutide, retatrutide) or lipotropic formulations such as LC216 Multi\u2011Peptide to study synergistic metabolic pathways. Always consult your institutional protocols for combination studies.<\/span><\/p>\n<h2 data-section-id=\"1rqn06o\" data-start=\"6615\" data-end=\"6661\">Documentation, COA, and Quality Information<\/h2>\n<p data-start=\"6663\" data-end=\"6796\">Professional buyers may request available documentation before discussing supply. This section should link directly to your COA page.<\/p>\n<h3 data-section-id=\"brqnwl\" data-start=\"6798\" data-end=\"6827\">Suggested Quality Message<\/h3>\n<p data-start=\"6829\" data-end=\"7137\">At Wuhan Top Miracle Peptides, verified buyers may contact our team to request available documentation, batch information, COA details, purity-related information, storage notes, and supply requirements for Tirzepatide. Documentation availability may vary by product, batch, country, and buyer qualification.<\/p>\n<p><a href=\"https:\/\/wuhantopmiraclepeptides.com\/index.php\/bulk-orders\/\"><strong data-start=\"11412\" data-end=\"11434\">Bulk Peptides Page<\/strong><\/a><br data-start=\"11434\" data-end=\"11437\" \/><a href=\"https:\/\/wuhantopmiraclepeptides.com\/index.php\/shipping-returns\/\"><strong data-start=\"11494\" data-end=\"11521\">Shipping &amp; Returns Page<\/strong><\/a><br data-start=\"11521\" data-end=\"11524\" \/><a href=\"https:\/\/wuhantopmiraclepeptides.com\/index.php\/contact-us\/\"><strong data-start=\"11578\" data-end=\"11594\">Contact Page<\/strong><\/a><br data-start=\"11682\" data-end=\"11685\" \/><strong data-start=\"11866\" data-end=\"11904\">MHRA medicine advertising guidance<\/strong><br data-start=\"11904\" data-end=\"11907\" \/><strong data-start=\"11959\" data-end=\"11988\">NICE tirzepatide guidance<\/strong><br data-start=\"11988\" data-end=\"11991\" \/><strong data-start=\"12039\" data-end=\"12089\">Google Search Central helpful content guidance<\/strong><br data-start=\"12089\" data-end=\"12092\" \/><strong data-start=\"12148\" data-end=\"12192\">ASA\/CAP health product advertising rules<\/strong><\/p>\n<h2 data-section-id=\"uyt3g6\" data-start=\"7461\" data-end=\"7491\">Professional Supply Regions<\/h2>\n<p data-start=\"7493\" data-end=\"7598\">Wuhan Top Miracle Peptides supports wholesale and professional product enquiries across multiple regions.<\/p>\n<h3 data-section-id=\"1ihzbnk\" data-start=\"7600\" data-end=\"7619\">Enquiry Regions<\/h3>\n<ul data-start=\"7621\" data-end=\"7718\">\n<li data-section-id=\"1anqy5e\" data-start=\"7621\" data-end=\"7639\">United Kingdom<\/li>\n<li data-section-id=\"w5ual1\" data-start=\"7640\" data-end=\"7650\">France<\/li>\n<li data-section-id=\"1d9bbc3\" data-start=\"7651\" data-end=\"7662\">Germany<\/li>\n<li data-section-id=\"1mveevh\" data-start=\"7663\" data-end=\"7672\">Spain<\/li>\n<li data-section-id=\"1abyjq\" data-start=\"7673\" data-end=\"7683\">Sweden<\/li>\n<li data-section-id=\"zt94rl\" data-start=\"7684\" data-end=\"7693\">Italy<\/li>\n<li data-section-id=\"17bvhhr\" data-start=\"7694\" data-end=\"7701\">USA<\/li>\n<li data-section-id=\"2seaf1\" data-start=\"7702\" data-end=\"7718\">Wider Europe<\/li>\n<\/ul>\n<p class=\"ds-markdown-paragraph\"><span class=\"\">From obesity and diabetes prevention to MASH resolution, cardiovascular risk factors, and emerging neuroprotective applications, <\/span><strong><span class=\"\">research peptide<\/span><\/strong><span class=\"\">\u00a0offers a well\u2011characterised, versatile dual\u2011agonist platform for advanced metabolic research. Its unique GIPR\/GLP\u20111R activation profile \u2013 supported by large\u2011scale clinical trials, mechanistic studies, and a growing body of preclinical evidence \u2013 provides a distinct advantage over selective GLP\u20111R agonists. By choosing high\u2011purity, lab\u2011verified\u00a0<\/span><strong><span class=\"\">Tirzepatide research peptide<\/span><\/strong><span class=\"\">\u00a0from Wuhan Top Miracle Peptides, you ensure that your research is built on a foundation of quality, reproducibility, and scientific integrity.<\/span><\/p>\n<p class=\"ds-markdown-paragraph\"><strong><span class=\"\">Ready to advance your metabolic research with Tirzepatide?<\/span><\/strong><span class=\"\">\u00a0Browse our product catalogue, request a wholesale quote, or contact our support team today to discuss your laboratory\u2019s specific needs. Place your order now and receive laboratory\u2011ready, GMP\u2011quality Tirzepatide delivered directly to your facility in the UK, EU, or USA.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Tirzepatide Research Peptide: Unlocking the Power of Dual GIP\/GLP\u20111 Agonism for Metabolic Studies If you are conducting advanced metabolic research, you have likely encountered\u00a0Tirzepatide research peptide. This synthetic 39\u2011amino\u2011acid peptide (LY3298176) is a first\u2011in\u2011class dual agonist of the glucose\u2011dependent insulinotropic polypeptide receptor (GIPR) and the glucagon\u2011like peptide\u20111 receptor (GLP\u20111R). Unlike traditional single\u2011receptor agonists, tirzepatide\u2019s dual [&#8230;]\n","protected":false},"featured_media":392,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[18],"product_tag":[268,270,345,232,266,321,346,348,347,349,269,239],"class_list":["post-1018","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-coa-peptide-supplier-uk","product_tag-europe-peptide-wholesale-supplier","product_tag-glp-1-gip-peptide-uk","product_tag-peptide-purity-uk","product_tag-professional-peptide-supplier-uk","product_tag-research-peptide-supplier-uk","product_tag-tirzepatide-documentation-request","product_tag-tirzepatide-peptide-uk","product_tag-tirzepatide-professional-enquiry","product_tag-tirzepatide-uk","product_tag-uk-peptide-supplier","product_tag-wholesale-peptides-uk","first","instock","shipping-taxable","purchasable","product-type-variable"],"_links":{"self":[{"href":"https:\/\/wuhantopmiraclepeptides.com\/index.php\/wp-json\/wp\/v2\/product\/1018","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wuhantopmiraclepeptides.com\/index.php\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/wuhantopmiraclepeptides.com\/index.php\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/wuhantopmiraclepeptides.com\/index.php\/wp-json\/wp\/v2\/comments?post=1018"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wuhantopmiraclepeptides.com\/index.php\/wp-json\/wp\/v2\/media\/392"}],"wp:attachment":[{"href":"https:\/\/wuhantopmiraclepeptides.com\/index.php\/wp-json\/wp\/v2\/media?parent=1018"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/wuhantopmiraclepeptides.com\/index.php\/wp-json\/wp\/v2\/product_brand?post=1018"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/wuhantopmiraclepeptides.com\/index.php\/wp-json\/wp\/v2\/product_cat?post=1018"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/wuhantopmiraclepeptides.com\/index.php\/wp-json\/wp\/v2\/product_tag?post=1018"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}